Stock Events

Stock Events

Emmaus Life Sciences Incorporation 

$0.02
4
-$0-1.96% Tuesday 19:46

Statistics

Day High
0.02
Day Low
0.02
52W High
0.02
52W Low
0.01
Volume
50,000
Avg. Volume
21,680
Mkt Cap
957,990
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

20MayExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Next
Next
-0.03
-0.02
-0
0.01
Expected EPS
N/A
Actual EPS
N/A

Financials

-38.75%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
33.31MRevenue
-12.91MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EMMA. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious genetic diseases, similar to Emmaus Life Sciences' focus on sickle cell disease.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences competes in the biopharmaceutical space, developing drugs for diseases like HIV, liver diseases, and other serious conditions, overlapping with Emmaus' therapeutic areas.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics is involved in genomic medicine, competing with Emmaus by developing gene therapies for genetic conditions, including hemoglobinopathies like sickle cell disease.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is in the space of gene editing, a direct competitor in developing treatments for genetic diseases, including sickle cell disease, which is a focus area for Emmaus.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine competes with Emmaus by working on gene editing technologies to treat genetic diseases, potentially including those in Emmaus' portfolio.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for genetic disorders, competing with Emmaus in the broader market for rare diseases.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on enzyme replacement therapies for rare genetic diseases, making it a competitor in the rare disease space where Emmaus operates.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals develops RNAi therapeutics for genetic diseases, competing with Emmaus in the market for novel genetic disease treatments.
Galapagos NV
GLPG
Mkt Cap2.09B
Galapagos NV is involved in the discovery and development of small molecule medicines, including for inflammatory diseases, potentially competing with Emmaus in the broader biotech space.

About

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Show more...
CEO
Mr. Willis C. Lee M.S.
Employees
34
Country
US
ISIN
US29137T1016

Listings

OTC Link
US
EMMA

0 Comments

Share your thoughts

FAQ

What is Emmaus Life Sciences Incorporation stock price today?▼
The current price of EMMA is $0.02 USD — it has decreased by -1.96% in the past 24 hours. Watch Emmaus Life Sciences Incorporation stock price performance more closely on the chart.
What is Emmaus Life Sciences Incorporation stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Emmaus Life Sciences Incorporation stocks are traded under the ticker EMMA.
Is Emmaus Life Sciences Incorporation stock price growing?▼
EMMA stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Emmaus Life Sciences Incorporation has showed a -12.28% decrease.
What is Emmaus Life Sciences Incorporation market cap?▼
Today Emmaus Life Sciences Incorporation has the market capitalization of 957,990
When is the next Emmaus Life Sciences Incorporation earnings date?▼
Emmaus Life Sciences Incorporation is going to release the next earnings report on May 20, 2026.
What is Emmaus Life Sciences Incorporation revenue for the last year?▼
Emmaus Life Sciences Incorporation revenue for the last year amounts to 33.31M USD.
What is Emmaus Life Sciences Incorporation net income for the last year?▼
EMMA net income for the last year is -12.91M USD.
How many employees does Emmaus Life Sciences Incorporation have?▼
As of April 01, 2026, the company has 34 employees.
In which sector is Emmaus Life Sciences Incorporation located?▼
Emmaus Life Sciences Incorporation operates in the Health Care sector.
When did Emmaus Life Sciences Incorporation complete a stock split?▼
The last stock split for Emmaus Life Sciences Incorporation was on July 17, 2019 with a ratio of 1:6.
Where is Emmaus Life Sciences Incorporation headquartered?▼
Emmaus Life Sciences Incorporation is headquartered in Torrance, US.